EGEN-2784
Asset
Gene-edited porcine kidney with glycan xenoantigen deletions, PERV inactivation, and seven human transgenes for xenotransplantation.
- Stage
- Phase 1
- Modality
- Cell therapy
- Target
- Not known
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1End-stage kidney disease
Phase 1, doi.org, 3 Sept 2026
In the full profile
- Owner and partners1
- Evidence for its targets1
Every asset’s record: target, stage, trials and the evidence behind it.